Research
Severe Covid-19 linked with molecular signs of brain ageing
Scientists have emphasised the importance of neurological follow-up in patients who have recovered from Covid-19.
Scientists have found similarities between biological pathways in the ageing brain and in patients affected by serve Covid-19 infection.
Although Covid-19 is primarily a respiratory disease, neurological symptoms have been described in many Covid-19 patients, including in recovered individuals.
Patients report symptoms including brain fog or lack of focused thinking, memory loss and depression, and scientists have demonstrated that patients with severe Covid-19 exhibit a drop in cognitive performance that mimics accelerated ageing.
But, the molecular evidence for Covid-19’s ageing effects on the brain is lacking.
In a series of experiments, scientists at Beth Israel Deaconess Medical Center (BIDMC), found that gene usage in the brains of patients with Covid-19 is similar to those observed in ageing brains.
Using a molecular profiling technique called RNA sequencing to measure the levels of every gene expressed in a particular tissue sample, the scientists assessed changes in gene expression profiles in the brains of Covid-19 patients and compared them to those changes observed in the brains of uninfected individuals.
The team’s analysis, published in Nature Aging, suggested that many biological pathways that change with natural ageing in the brain also changed in patients with severe Covid-19.
“Ours is the first study to show that Covid-19 is associated with the molecular signatures of brain ageing,” said co-first and co-corresponding author Maria Mavrikaki, PhD, an instructor of pathology at BIDMC and Harvard Medical School.
“We found striking similarities between the brains of patients with Covid-19 and aged individuals.”
Mavrikaki and colleagues analysed a total of 54 postmortem human frontal cortex tissue samples from adults 22 to 85 years old. Of these, 21 samples were from severe Covid-19 patients and one from an asymptomatic Covid-19 patient who died. These samples were age- and sex-matched to uninfected controls with no history of neurological or psychiatric disease.
The scientists also included an age-and sex- matched uninfected Alzheimer’s disease case for analysis as a control to a Covid-19 case which had co-morbid Alzheimer’s disease, as well as an additional independent control group of uninfected individuals with a history of intensive care or ventilator treatment.
“We observed that gene expression in the brain tissue of patients who died of Covid-19 closely resembled that of uninfected individuals 71-years-old or older,” said co-first author Jonathan Lee, PhD, a postdoctoral research fellow at BIDMC and Harvard Medical School.
“Genes that were upregulated in ageing were upregulated in the context of severe COVID-19; likewise, genes downregulated in ageing were also downregulated in severe Covid-19. While we did not find evidence that the SARS-CoV-2 virus was present in the brain tissue at the time of death, we discovered inflammatory patterns associated with Covid-19. This suggests that this inflammation may contribute to the ageing-like effects observed in the brains of patients with Covid-19 and long covid.”
Senior and co-corresponding author Frank Slack, PhD, director of the Institute for RNA Medicine at BIDMC and the Shields Warren Mallinckrodt Professor of Medical Research at Harvard Medical School, said: “Given these findings, we advocate for neurological follow-up of recovered Covid-19 patients.
“We also emphasise the potential clinical value in modifying the factors associated with the risk of dementia — such as controlling weight and reducing excessive alcohol consumption — to reduce the risk or delay the development of ageing-related neurological pathologies and cognitive decline.”
Better understanding of the molecular mechanisms underlying brain ageing and cognitive decline in Covid-19 could lead to the development of novel therapeutics to address cognitive decline observed in Covid-19 patients.
The team is now trying to understand what drives the ageing-like effects in the brains of Covid-19 patients.